Catalog No.
Product Name
Application
Product Information
Citations
-
FLT3 Inhibitor
FLT3-IN-19 is a potent and selective inhibitor of the FLT3 receptor tyrosine kinase, exhibiting an IC50 of 0.213 nM. This compound is primarily utilized in the research of acute myeloid leukemia (AML), facilitating studies on FLT3-dependent signaling pathways and potential therapeutic interventions. Its high specificity makes it an invaluable tool for understanding the molecular mechanisms underlying FLT3-driven malignancies. -
FLT3/Haspin Inhibitor
HSK205 is a potent dual inhibitor of FLT3 and Haspin, exhibiting an IC50 of 0.187 nM for FLT3. This compound demonstrates significant antitumor activity, making it a valuable tool in cancer research. Its dual targeting provides insights into the therapeutic potential for FLT3-driven malignancies and the role of Haspin in cell cycle regulation. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-3 is a highly effective inhibitor of PDGFRα and FLT3, exhibiting IC50 values of 0.153 μM and 0.004 μM, respectively. This compound serves as a valuable tool in the investigation of acute myeloid leukemia and chronic eosinophilic leukemia. Its potent inhibitory activity against key receptors makes it a significant candidate for related biomedical research applications. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-3 is a highly selective inhibitor targeting FLT3 internal tandem duplications (FLT3-ITD), demonstrating potent activity with IC50 values of 0.3 nM for FLT3D835Y, 0.4 nM for FLT3, and 0.9 nM for FLT3-ITD. This compound effectively inhibits FLT3 phosphorylation and exhibits significant antiproliferative effects against acute myeloid leukemia cell lines. It serves as a valuable tool in research aimed at understanding and developing therapies for FLT3-ITD associated malignancies. -
FLT3/IRAK4 Inhibitor
Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor that demonstrates significant antitumor activity. It is particularly relevant for research involving myeloid leukemia, where it may offer insights into therapeutic strategies targeting these pathways. Its unique mechanism of action makes it a valuable tool for investigating the roles of FLT3 and IRAK4 in cancer biology. -
PROTAC FLT3-ITD Degrader
PF15 is a PROTAC designed to target FLT3 kinase through its ligands linked with CRBN. This highly selective FLT3-ITD degrader exhibits a DC50 of 76.7 nM, effectively inhibiting the proliferation of FLT3-ITD-positive cells. PF15 down-regulates the phosphorylation of FLT3 and STAT5, demonstrating significant anti-tumor activity in mouse models, making it a valuable tool for leukemia research. -
Flt3 Inhibitor
D-65476 is a selective inhibitor of the Flt3 receptor tyrosine kinase, primarily acting in the absence of IL-3. It effectively suppresses the proliferation of TEL-Flt3 transfected BA/F3 cells, demonstrating an IC50 value of 0.2 μM. This compound is a valuable tool for exploring Flt3-driven leukemias and related therapeutic strategies. -
FLT3 Inhibitor
LT-850-166 is a potent inhibitor of FLT3, a receptor tyrosine kinase involved in hematopoiesis and leukemogenesis. It effectively targets various FLT3 mutations, demonstrating significant potential in the treatment of acute myeloid leukemia (AML) and other FLT3-driven malignancies. This compound serves as a valuable tool for research applications focused on understanding FLT3 signaling pathways and the development of targeted cancer therapies. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-2 is a selective inhibitor of FLT3 internal tandem duplications (FLT3-ITD), exhibiting IC50 values of 0.3 nM for FLT3D835Y, 0.4 nM for FLT3, and 1.0 nM for FLT3-ITD. This compound effectively blocks FLT3 phosphorylation and demonstrates robust antiproliferative effects on acute myeloid leukemia cell lines. It is a valuable tool for research into targeted therapies for leukemia and related disorders. -
FLT3/ITD Mutation Inhibitor
HP1328 is a potent inhibitor of the FLT3 receptor tyrosine kinase specifically targeting the FLT3/ITD mutation. This benzoimidazole scaffold-based compound demonstrates significant efficacy in reducing leukemia burden and prolonging survival in murine models of FLT3/ITD leukemia. HP1328 is valuable for research focused on targeted therapies for acute myeloid leukemia and advancing understanding of FLT3-related pathophysiology. -
FLT3 Inhibitor
FLT3-IN-11 is a potent and selective inhibitor of FLT3 kinase, exhibiting IC50 values of 7.22 nM and 4.95 nM for wild-type FLT3 and the FLT3-D835Y mutant, respectively. This compound demonstrates over 1000-fold selectivity for FLT3 compared to c-KIT. FLT3-IN-11 shows significant anti-acute myeloid leukemia (AML) activity, with an IC50 of 3.2 nM in MV4-11 cell assays, making it a valuable tool for research in AML therapeutics. -
FLT3 Inhibitor
FLT3-IN-32 TFA is a selective inhibitor of FLT3, targeting both FLT3-ITD and FLT3-D835Y with IC50 values of 2.40 nM and 3.83 nM, respectively. This compound effectively inhibits the proliferation and survival of human MV4-11 cells, demonstrating an IC50 of 0.07 nM. FLT3-IN-32 TFA is valuable for research focused on acute myeloid leukemia (AML), providing insights into targeted therapeutic strategies. -
FLT3 Inhibitor
MolPort-002-705-878 is a selective inhibitor of FMS-like tyrosine kinase 3 (FLT3) with a binding affinity of -11.33 kcal/mol. It effectively inhibits the proliferation of FLT3-mutated acute myeloid leukemia (AML) cells, making it a valuable tool for research in this domain. This compound holds potential for advancing studies focused on FLT3-mutated AML therapies. -
FLT3 Inhibitor
LT-540-717 is a potent inhibitor of the FLT3 receptor, exhibiting an IC50 of 0.62 nM. It demonstrates significant antiproliferative activity against cells harboring various acquired FLT3 mutations, including FLT3 ITD, D835V, F691L, and D835Y. Due to its selective inhibition of FLT3, LT-540-717 is a valuable candidate for research focused on acute myeloid leukemia (AML) treatment strategies. -
Mer/Flt3 Tyrosine Kinase Inhibitor
UNC1666 is an ATP-competitive dual-target inhibitor of the Mer and Flt3 tyrosine kinases, exhibiting potent inhibition with IC50 values of 0.55 nM and 0.69 nM, and Ki values of 0.16 nM and 0.67 nM, respectively. This compound effectively inhibits the kinase activities of Mer and Flt3, leading to decreased phosphorylation levels and suppression of downstream pro-survival signaling pathways such as Erk1/2, Akt, and Stat. Additionally, UNC1666 promotes apoptosis and reduces colony formation in acute myeloid leukemia cells, making it a valuable tool for research focused on this malignancy. -
FLT3/FLT3-ITD Inhibitor
FLT3/ITD-IN-5 is a potent inhibitor of FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is designed for use in cancer research, providing valuable insights into therapies targeting FLT3 mutations commonly found in acute myeloid leukemia (AML). Its high selectivity makes it an essential tool for studying FLT3 signaling pathways and developing targeted treatments. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-4 is a selective inhibitor of FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD), exhibiting an IC50 of 2.3 nM. This compound demonstrates potent biological activity against FLT3-ITD mutations, making it valuable for research in acute myeloid leukemia. FLT3/ITD-IN-4 is ideal for studies exploring targeted therapies and the underlying mechanisms of FLT3-mediated signaling. -
FLT3 Receptor Antagonist
BDT001 is a selective FLT3 receptor antagonist that inhibits the signaling pathways associated with FLT3 activation. This compound demonstrates significant potential in research applications focused on pain disorders, cancer, and autoimmune diseases by modulating the activity of FLT3, a receptor implicated in cellular proliferation and survival. BDT001 serves as a valuable tool for investigating therapeutic strategies targeting FLT3-related pathologies. -
BTK/FLT3 Inhibitor
RSH-7 is a potent inhibitor of Bruton's tyrosine kinase (BTK) and Fms-like tyrosine kinase 3 (FLT3), exhibiting IC50 values of 47 nM and 12 nM, respectively. This compound induces apoptosis and demonstrates significant antiproliferative activity. By inhibiting BTK and FLT3 signaling pathways, RSH-7 is a valuable tool for research in oncology and targeted therapies for hematological malignancies. -
FLT3 Inhibitor
FLT3-IN-26 is a potent FLT3 inhibitor with a pIC50 value of 7.367. This compound demonstrates significant biological activity against FLT3, making it a valuable tool for investigating acute myeloid leukemia. Its specificity and efficacy facilitate research into targeted therapies for this malignancy. -
FLT3 Inhibitor
FLT3-IN-12 is a selective and orally bioavailable inhibitor of the FLT3 kinase, demonstrating IC50 values of 1.48 nM for FLT3-WT and 2.87 nM for the FLT3-D835Y mutant. This compound exhibits exceptional selectivity over c-KIT, surpassing 1000-fold. Additionally, FLT3-IN-12 showcases potent anti-acute myeloid leukemia (AML) activity, with an IC50 of 0.75 nM against the MV4-11 cell line, making it a valuable tool for the study of FLT3-driven malignancies and potential therapeutic applications in AML. -
FLT3 Inhibitor
FLT3-IN-15 is a potent and orally bioavailable inhibitor of the FLT3 receptor, exhibiting IC50 values of 0.87 nM for FLT3 and 0.32 nM for the FLT3/D835Y mutant. This compound is primarily utilized in research related to acute myeloid leukemia, providing insights into the therapeutic potential of targeting aberrant FLT3 signaling pathways in cancer treatment. -
FLT3 inhibitor
FLT3-IN-23 is a potent inhibitor of the Fms-like tyrosine kinase 3 (FLT3), exhibiting an IC50 value of 7.42 nM. It demonstrates significant antiproliferative activity against BaF3 cells harboring multiple FLT3 tyrosine kinase domain (TKD) and internal tandem duplication (ITD) mutations. This compound serves as a valuable tool for research in targeted therapies for FLT3-mutant leukemias. -
FLT3/D835Y Inhibitor
FLT3/D835Y-IN-1 is a potent and selective inhibitor targeting FLT3 and the FLT3/D835Y mutant with IC50 values of 0.26 nM and 0.18 nM, respectively. This orally active compound demonstrates significant inhibition of tumor growth and exhibits anticancer efficacy, making it a valuable tool for research into acute myeloid leukemia (AML). FLT3/D835Y-IN-1 provides a targeted approach for studying the effects of FLT3 mutations in cellular and animal models of AML. -
FLT3 Inhibitor
CHEMBL4444839 is a potent FLT3 inhibitor that plays a crucial role in the study of acute myeloid leukemia (AML). Its ability to selectively target FLT3 makes it a valuable tool for investigating the molecular mechanisms of AML and developing potential therapeutic strategies. Researchers can leverage CHEMBL4444839 to explore the effects of FLT3 inhibition on cell proliferation and survival in AML models. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-1 is a selective inhibitor of the platelet-derived growth factor receptor alpha (PDGFRα) and the Fms-like tyrosine kinase 3 (FLT3), demonstrating IC50 values of 0.036 μM and 0.003 μM, respectively. This compound is particularly relevant for investigations into acute myeloid leukemia (AML) and chronic eosinophilic leukemia (CEL), providing a valuable tool for exploring therapeutic strategies targeting these malignancies. Researchers utilizing PDGFRα/FLT3-ITD-IN-1 can gain insights into the molecular mechanisms underlying these hematological disorders. -
FLT3 Inhibitor
FLT3-IN-18 is a highly selective inhibitor of FLT3, exhibiting an IC50 value of 0.003 μM. This compound effectively induces apoptosis and enforces G1 phase cell cycle arrest in FLT3-positive cells. Additionally, FLT3-IN-18 inhibits both FLT3 and STAT5 phosphorylation, making it a valuable tool for investigating the signaling pathways involved in acute myeloid leukemia (AML). Its potency and specificity position FLT3-IN-18 as a crucial reagent for researching FLT3-driven malignancies. -
FLT3 Inhibitor
TTT 3002 is a potent FLT3 inhibitor that effectively targets FLT3 phosphorylation in the presence of activating mutations at residue D835, demonstrating an IC50 of 0.2 nM. This compound is valuable for research in acute myeloid leukemia (AML) and other related hematologic malignancies. Its specificity and efficacy make it a crucial tool for investigating FLT3 signaling pathways and developing targeted therapies. -
FLT3/ITD Mutation Inhibitor
HP1142 is a selective inhibitor of the FLT3 receptor tyrosine kinase, specifically targeting the FLT3/ITD mutation. This compound, derived from a benzoimidazole scaffold, demonstrates significant efficacy in inhibiting FLT3 signaling pathways. HP1142 is primarily utilized in research focused on FLT3/ITD mutated leukemia, providing valuable insights into therapeutic strategies for this malignancy. -
FLT3/CDK4 Inhibitor
FLT3/CDK4-IN-1 is a highly selective, orally active dual inhibitor targeting FLT3 and CDK4, demonstrating IC50 values of 11 nM and 7 nM, respectively. This compound exhibits significant antiproliferative activity against specific cancer cell lines and shows promising antitumor effects in vivo. FLT3/CDK4-IN-1 is suitable for research applications focused on cancer biology, particularly in exploring pathways associated with leukemias and solid tumors. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-2 is a selective inhibitor targeting PDGFRα and FLT3, exhibiting IC50 values greater than 20 μM and 1.654 μM, respectively. This compound demonstrates significant biological activity relevant to the treatment of acute myeloid leukemia and chronic eosinophilic leukemia. Its efficacy in modulating these pathways makes it a valuable tool for investigational research in cancer therapeutics. -
PDGFR/TEL-PDGFR/FLT3/KIT Inhibitor
AGL 2043 is a potent inhibitor of PDGFR, TEL-PDGFR, FLT3, and KIT kinases, exhibiting an IC50 value of 0.8 μM against PDGFR. This compound demonstrates significant biological activity by effectively reducing porcine cardiac smooth muscle cell proliferation and mitigating balloon-induced vascular stenosis. AGL 2043 presents promising applications in the development of anti-restenotic and anticancer therapies. -
FLT3/IRAK1/4 Inhibitor
NCGC1481 is a potent inhibitor of FLT3, IRAK1, and IRAK4, displaying IC50 values of <0.5 nM, 22.6 nM, and 0.8 nM, respectively. This compound effectively mitigates the adaptive resistance of leukemia cells to FLT3 inhibitors, demonstrating significant antileukemic activity. NCGC1481 is suitable for research focused on leukemia treatment and the modulation of key signaling pathways involved in cancer cell survival and proliferation. -
FLT3 Inhibitor
Flt-3 Inhibitor III is a selective inhibitor of the FLT3 kinase with a potent IC50 value of 50 nM. This compound demonstrates minimal activity against other kinases, thereby ensuring specificity. Flt-3 Inhibitor III is primarily utilized in research applications related to cancer biology, particularly in studies investigating FLT3 mutations in acute myeloid leukemia (AML). Its ability to inhibit FLT3 activity underscores its potential as a therapeutic agent in targeted cancer therapies. -
MERTK/FLT3 Inhibitor
MRX-2843 hydrochloride is an orally active, ATP-competitive inhibitor targeting MERTK and FLT3 tyrosine kinases. It demonstrates potent enzymatic inhibitory activity with IC50 values of 1.3 nM for MERTK and 0.64 nM for FLT3. This compound is ideal for research applications investigating cancer therapies and related signaling pathways involving these kinases. -
FLT3 Inhibitor
AAE871 is a potent type I FLT3 inhibitor, exhibiting an IC50 value of 0.034 µM. It demonstrates significant biological activity in inhibiting FLT3 signaling, making it a valuable tool for investigating acute myeloid leukemia (AML) and related hematological malignancies. AAE871 is useful in preclinical studies aimed at understanding FLT3-mediated pathways and their role in cancer progression. -
FLT3 Inhibitor
FLT3-IN-38 is a selective FLT3 inhibitor that targets the FLT3 receptor tyrosine kinase, which is implicated in hematologic malignancies. This compound also exhibits off-target effects by inhibiting serine/threonine kinase haspin, a critical regulator of mitotic signaling. FLT3-IN-38 is suitable for cancer research applications, particularly in studies focused on the treatment of FLT3-mutated leukemias. -
FLT3 Inhibitor
FLT3-IN-14 is a potent inhibitor of the FLT3 receptor, exhibiting IC50 values of 5.6 nM for wild-type FLT3 and 1.4 nM for the FLT3-ITD mutant. This compound effectively reduces the phosphorylation of FLT3 at Y591, leading to cell cycle arrest in the G1 phase and subsequent induction of apoptosis. In preclinical studies, FLT3-IN-14 has demonstrated significant efficacy in reducing tumor growth within MV4-11 xenograft mouse models, highlighting its potential for therapeutic applications in FLT3-related malignancies. -
JAK2/Bcr-Abl/FLT3 Inhibitor
LS-104 is a non-ATP-competitive inhibitor targeting JAK2, Bcr-Abl, and FLT3. It effectively induces apoptosis in JAK2V617F-positive cells while inhibiting JAK2 autophosphorylation and downstream signaling pathways. Additionally, LS-104 demonstrates significant cytotoxic effects and inhibits the proliferation of FLT3-expressing leukemic cells. This hydroxystyryl-acrylonitrile compound holds potential for research into myeloproliferative disorders and refractory or relapsed hematologic malignancies. -
FLT3 Inhibitor
AFG206 is a first-generation ATP-competitive "type II" inhibitor of FLT3. This compound effectively inhibits cell proliferation with an IC50 of approximately 0.1 µM by inducing apoptosis in FLT3-ITD-Ba/F3 and D835Y-Ba/F3 cell lines. AFG206 holds significant promise for research applications related to acute myeloid leukemia. -
FLT3 Inhibitor
BPR1J-340 is a potent inhibitor of FLT3, exhibiting an IC50 of approximately 25 nM. It effectively inhibits the phosphorylation of FLT3 and STAT5, inducing apoptosis in FLT3-ITD positive acute myeloid leukemia (AML) cells. This compound demonstrates considerable anti-tumor activities, making it a valuable tool for research in cancer biology and therapeutic strategies targeting FLT3 dysregulation. -
FLT3 Inhibitor
Tandutinib sulfate is a selective inhibitor of FLT3, exerting its effects with an IC50 of 0.22 μM. It also targets c-Kit and PDGFR, with IC50 values of 0.17 μM and 0.20 μM, respectively. This compound is particularly relevant for research in acute myelogenous leukemia (AML) and is noted for its capacity to cross the blood-brain barrier, expanding its potential applications in hematological malignancies and central nervous system studies. -
FLT3 Inhibitors
FLT3-IN-32 is a highly selective, orally bioavailable inhibitor of the FLT3 receptor tyrosine kinase. It effectively targets FLT3-activating mutations, promoting apoptosis in malignant cells. In vivo studies demonstrate significant anti-tumor efficacy in MV4-11 xenograft models within NOD/SCID mice, leading to notable extensions in survival. FLT3-IN-32 is valuable for research applications focused on acute myeloid leukemia. -
FLT3 Inhibitor
HSB401 is an orally active FLT3 inhibitor with IC50 values of 28, 5, 72, and 51 nM for FLT3-WT, FLT3-D835Y, FLT3-ITD-F691L, and FLT3-ITD, respectively. It effectively downregulates FLT3 signaling, leading to cell cycle arrest and apoptosis in sensitive cells. Notably, HSB401 spares c-KIT inhibition, minimizing the risk of myelosuppression. This compound has demonstrated significant tumor growth suppression in the MV4-11 xenograft mouse model and is valuable for research in acute myeloid leukemia. -
FLT3 Inhibitor
SILA-123 is a potent FLT3 inhibitor, demonstrating IC50 values of 2.1 nM for FLT3-WT and 1.0 nM for FLT3-ITD. This compound effectively inhibits FLT3 phosphorylation and disrupts downstream signaling pathways, resulting in apoptosis through cell cycle arrest in the G0/G1 phase. SILA-123 is particularly valuable in research related to acute myeloid leukemia. -
FLT3 Inhibitor
JH-IX-179 is a potent FLT3 inhibitor with an IC50 of 4 nM for FLT3-ITD and 10 nM for FLT3-D835Y variants. This compound effectively induces cell cycle arrest in the G1 phase and promotes apoptosis in cells expressing the FLT3-ITD mutation. JH-IX-179 is primarily utilized in research focused on acute myeloid leukemia (AML), providing valuable insights into therapeutic strategies targeting FLT3 signaling pathways. -
FLT3/HDAC Inhibitor
HDAC-IN-63 is a dual inhibitor targeting both FLT3 and HDAC, with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1. It demonstrates potent inhibition of MV4-11 cell proliferation, with an IC50 of 92 nM, and effectively induces apoptosis while arresting the cell cycle in MV4-11 cells. This compound serves as a valuable research tool for the study of acute myeloid leukemia (AML) and the exploration of novel therapeutic strategies. -
FLT3 Inhibitor
FLT3-IN-31 is a potent inhibitor of FLT3, exhibiting IC50 values of 0.16 nM for the wild-type FLT3 receptor and 2.4 nM for the FLT3-D835Y mutant. It demonstrates significant antiproliferative activity by decreasing the protein expression of phosphorylated FLT3, STAT5, and ERK. Additionally, FLT3-IN-31 induces apoptosis and triggers cell cycle arrest at the G1 phase, making it a valuable tool for research in targeted cancer therapies and leukemia treatment. -
FLT3/HDAC Inhibitor
FLT3/HDAC-IN-3 is a dual inhibitor targeting FLT3 and HDAC, with a potent inhibitory effect on FLT3 (IC50 = 14 nM) and HDAC isoforms, including HDAC1 (IC50 = 27 nM) and HDAC6 (IC50 = 20 nM). This compound demonstrates selective inhibition, exhibiting reduced activity against HDAC8 and no activity toward HDAC4. FLT3/HDAC-IN-3 has shown anti-proliferative effects across various hematological malignancy cell lines and demonstrates efficacy in the Jeko-1 xenograft model without significant toxicity. It is suitable for research focused on hematological malignancies and the role of dual inhibition in therapeutic strategies. -
FLT3/JAK2 Inhibitor
JAK2/FLT3-IN-3 is a potent dual inhibitor of FLT3 and JAK2, exhibiting IC50 values of 2.01 nM for JAK2, 0.51 nM for FLT3, and 104.40 nM for JAK3. This compound induces apoptosis in cancer cells and demonstrates significant antitumor activity. Its ability to inhibit both FLT3 and JAK2 pathways makes it a valuable tool for research related to hematological malignancies and targeted cancer therapies.
